A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Drug Metabolism And Disposition

• Publication date

  2013-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.112.050161PMID 23355638PMCID PMC3608458
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantitative Prediction of CYP2B6 Induction by Estradiol During Pregnancy: Potential Explanation for Increased Methadone Clearance During Pregnancy

  2013cited by this paper
• Prediction of Relative In Vivo Metabolite Exposure from In Vitro Data Using Two Model Drugs: Dextromethorphan and Omeprazole

  2012influential reference
• Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings.

  2012influential reference
• A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4

  2012cited by this paper
• A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.

  2012cited by this paper
• Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy

  2012influential reference
• A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction

  2012influential reference
• Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture

  2011cited by this paper
• Physiologically-based pharmacokinetics in drug development and regulatory science.

  2011cited by this paper
• Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan

  2010influential reference
• Pharmacokinetics of Metformin during Pregnancy

  2010influential reference
• Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-Based Simulator

  2010cited by this paper
• Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes

  2010cited by this paper
• CYP2D6 Mediates 4-Hydroxylation of Clonidine In Vitro: Implication for Pregnancy-Induced Changes in Clonidine Clearance

  2010influential reference
• A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates.

  2009cited by this paper
• Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy

  2009influential reference
• Clonidine Pharmacokinetics in Pregnancy

  2009influential reference
• Kinetic and Thermodynamic Assessment of Binding of Serotonin Transporter Inhibitors

  2008cited by this paper
• Lack of interaction of the NMDA receptor antagonists dextromethorphan and dextrorphan with P-glycoprotein.

  2008cited by this paper
• Prediction of intestinal first-pass drug metabolism.

  2007influential reference
• Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions

  2007cited by this paper
• Alterations in drug disposition during pregnancy: implications for drug therapy.

  2007cited by this paper
• Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes

  2007influential reference
• Alterations in drug disposition during pregnancy:

  2007cited by this paper
• Quantitative structure-property relationship study of n-octanol-water partition coefficients of some of diverse drugs using multiple linear regression.

  2007cited by this paper
• Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

  2005influential reference
• DEXTROMETHORPHAN TO DEXTRORPHAN URINARY METABOLIC RATIO DOES NOT REFLECT DEXTROMETHORPHAN ORAL CLEARANCE

  2005influential reference
• IN VITRO-IN VIVO EXTRAPOLATION OF CYP2D6 INACTIVATION BY PAROXETINE: PREDICTION OF NONSTATIONARY PHARMACOKINETICS AND DRUG INTERACTION MAGNITUDE

  2005influential reference
• The effect of three different oral doses of verapamil on the disposition of theophylline

  2005cited by this paper
• Modulation of Metoprolol Pharmacokinetics and Hemodynamics by Diphenhydramine Coadministration during Exercise Testing in Healthy Premenopausal Women

  2005influential reference
• IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM

  2005influential reference
• Pregnancy-Induced Changes in Pharmacokinetics

  2005cited by this paper
• Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.

  2005influential reference
• Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects

  2004influential reference
• Longitudinal effects of pregnancy on the pharmacokinetics of theophylline

  2004influential reference
• New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man

  2004influential reference
• The Effect of Echinacea (Echinacea purpurea Root) on Cytochrome P450 Activity in Vivo

  2004influential reference
• Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow

  2004influential reference
• Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

  2003influential reference
• Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.

  2003cited by this paper
• Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?

  2001influential reference
• The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.

  2001cited by this paper
• Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity

  2000influential reference
• In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity.

  1999cited by this paper
• The antitussive effect of dextromethorphan in relation to CYP2D6 activity.

  1999influential reference
• Induction of CYP2D6 in pregnancy

  1997influential reference
• The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans

  1996influential reference
• Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N‐demethylation

  1996influential reference
• Metoprolol metabolism via cytochrome P4502D6 in ethnic populations.

  1996influential reference
• Theophylline metabolism in human liver microsomes: inhibition studies.

  1996influential reference
• Metabolic Fate of Clonidine (IV): Plasma Protein Binding of Clonidine In vitro and In vivo and Transfer to Fetus and Milk in Rats after Subcutaneous Administration of Clonidine

  1996influential reference
• Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group.

  1995cited by this paper
• Safety, Tolerability, and Pharmacokinetics of the N-Methyl-d-Aspartate Antagonist Dextrorphan in Patients With Acute Stroke

  1995cited by this paper
• Comparative pharmacokinetics of oral versus sublingual clonidine.

  1994cited by this paper
• Comparison of the Pharmacokinetics, Pharmacodynamics, and Safety of Oral (Catapres) and Transdermal (M‐5041T) Clonidine in Healthy Subjects

  1994cited by this paper
• The relationship between paroxetine and the sparteine oxidation polymorphism

  1992influential reference
• Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism

  1992influential reference
• A review of the metabolism and pharmacokinetics of paroxetine in man

  1989cited by this paper
• Effect of calcium channel blockers on theophylline disposition

  1988cited by this paper
• Drug protein binding in chronic renal failure: evaluation of nine drugs.

  1988influential reference
• Theophylline pharmacokinetics in pregnancy.

  1987influential reference
• Goodman and Gilman's The Pharmacological Basis of Therapeutics

  1986cited by this paper
• Goodman and Gilman's the Pharmacological Basis of Therapeutics

  1986cited by this paper
• Update on the pharmacodynamics and pharmacokinetics of theophylline.

  1985influential reference
• Pregnancy‐induced increase in metoprolol metabolism

  1985influential reference
• Temporal variation in the disposition of theophylline and its metabolites

  1985influential reference
• Theophylline A “State of the Art” Review

  1983cited by this paper
• Nonlinear theophylline elimination

  1982influential reference
• Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy.

  1981influential reference
• CLONIDINE DISTRIBUTION IN THE RAT: TEMPORAL RELATIONSHIP BETWEEN TISSUE LEVELS AND BLOOD PRESSURE RESPONSE

  1980cited by this paper
• The molecular conformation of clonidine hydrochloride, an α-adrenergic agonist

  1979cited by this paper

• A Validated Whole-Body PBPK Model of Dextromethorphan and Its Metabolites for Genotype-Based Prediction of CYP2D6 Phenotype and Urinary Metabolic Ratio

  2025cites this paper
• Rosuvastatin PBPK Modeling: Incorporating Liver Concentrations and Effects of Ethnicity, Genetic Polymorphisms, Lactone Formation, DDI and Pregnancy

  2025cites this paper
• Regulation of expression and activity of hepatic transporters by pregnancy-related hormones in HepaRG cells.

  2025cites this paper
• Optimal Dosing Recommendations of Clonidine in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.

  2024cites this paper
• The ADME characteristics of siRNA therapeutics and the opportunity to predict disposition in pregnant women.

  2024cites this paper
• Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective

  2022cites this paper
• Opioid exposure during pregnancy and the risk of congenital malformation: a meta-analysis of cohort studies

  2022cites this paper
• Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups

  2022cites this paper
• Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model

  2022cites this paper
• Predicting Regional Respiratory Tissue and Systemic Concentrations of Orally Inhaled Drugs through a Novel PBPK Model

  2022cites this paper
• Predicting Human Fetal Drug Exposure Through Maternal‐Fetal PBPK Modeling and In Vitro or Ex Vivo Studies

  2022cites this paper
• Antidepressants and Antipsychotics in Human Pregnancy: Transfer Across the Placenta and Opportunities for Modeling Studies

  2022cites this paper
• Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan

  2022cites this paper
• Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone

  2022cites this paper
• When special populations intersect with drug–drug interactions: Application of physiologically‐based pharmacokinetic modeling in pregnant populations

  2021cites this paper
• The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions

  2021cites this paper
• Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models

  2021influential citation
• Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development

  2021cites this paper
• Prediction of Pregnancy-Induced Changes in Secretory and Total Renal Clearance of Drugs Transported by Organic Anion Transporters

  2021cites this paper
• A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy

  2021cites this paper
• PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Kidney in Pregnant Subjects and Fetus

  2021cites this paper
• Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study.

  2021cites this paper
• Drug Development Research in Pregnant and Lactating Women.

  2021cites this paper
• Exploring the Use of Serum‐Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Hepatic Cytochromes P450 and Organic Anion Transporting Polypeptides

  2021cites this paper
• Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure

  2021cites this paper
• Model‐Informed Dose Optimization in Pregnancy

  2020cites this paper
• Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions

  2020cites this paper
• Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation

  2020cites this paper
• Drug dosing during pregnancy—opportunities for physiologically based pharmacokinetic models

  2020cites this paper
• Dose Optimization of Chloroquine by Pharmacokinetic Modeling During Pregnancy for the Treatment of Zika Virus Infection.

  2019cites this paper
• Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Caffeine Disposition in Pregnancy.

  2019cites this paper
• A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab

  2019cites this paper
• Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?

  2019cites this paper
• Methodological Approaches to Evaluate Fetal Drug Exposure.

  2019cites this paper
• SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers?

  2019cites this paper
• Sex-Gender Variable: Methodological Recommendations for Increasing Scientific Value of Clinical Studies

  2019cites this paper
• Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam

  2019cites this paper
• Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice.

  2019cites this paper
• Placental transfer of xenobiotics in pregnancy physiologically-based pharmacokinetic models: Structure and data

  2019cites this paper
• Profiling of Drug-Metabolizing Enzymes and Transporters in Human Tissue Biopsy Samples: A Review of the Literature

  2019cites this paper
• Clinical Significance and Regulatory Framework for the Evaluation of Organic Anion Transporting Polypeptide 1B-Based Drug-Drug Interactions

  2019cites this paper
• Pharmacokinetics and PBPK Models

  2018cites this paper
• A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways

  2018cites this paper
• COMMENTARY Inclusion of pregnant and breastfeeding women in research – efforts and initiatives

  2018cites this paper
• Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models

  2018influential citation
• Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations

  2018cites this paper
• Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers

  2018cites this paper
• Inclusion of pregnant and breastfeeding women in research – efforts and initiatives

  2018cites this paper
• Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps

  2018cites this paper
• Clinical implications of selective serotonin reuptake inhibitors-selective serotonin norepinephrine reuptake inhibitors pharmacogenetics during pregnancy and lactation.

  2018cites this paper
• Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum

  2018cites this paper
• Drug Metabolism in Pregnancy

  2017cites this paper
• DMD # 76455 1 PHYSIOLOGICALLY BASED PHARMACOKINETIC ( PBPK ) MODEL OF THE CYP 2 D 6 PROBE ATOMOXETINE : EXTRAPOLATION TO SPECIAL POPULATIONS AND DRUG-DRUG INTERACTIONS

  2017cites this paper
• Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions s

  2017cites this paper
• Theophylline and Other Methylxanthines

  2017cites this paper
• Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions

  2017cites this paper
• A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways

  2017cites this paper
• Physicochemical and Biopharmaceutical Factors Affecting Hepatic/Intestinal First-Pass Effect

  2017cites this paper
• Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine.

  2017cites this paper
• Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling

  2017cites this paper
• Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the Model for Passive Placental Permeability Drugs

  2017influential citation
• Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses

  2017cites this paper
• Therapeutic Drug Monitoring in Pregnancy

  2016cites this paper
• Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.

  2016cites this paper
• The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update

  2016cites this paper
• Prédiction du passage transplacentaire in-vivo des médicaments à partir de modèles ex-vivo

  2016cites this paper
• Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.

  2016cites this paper
• Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy

  2016cites this paper
• Predicting Maternal-Fetal Disposition of Drugs Using In Vitro and In Silico Tools

  2016cites this paper
• Reproductive Psychiatry: The Gap Between Clinical Need and Education.

  2015cites this paper
• The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding.

  2015cites this paper
• Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.

  2015cites this paper
• Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy

  2015cites this paper
• The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding

  2015cites this paper
• Physiologically Based Pharmacokinetic ( PBPK ) Modeling and Simulation Approaches : A Systematic Review of Published Models , Applications , and Model Verification s

  2015influential citation
• Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients.

  2015cites this paper
• Safety assessment for ethanol-based topical antiseptic use by health care workers: Evaluation of developmental toxicity potential.

  2015cites this paper
• Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model

  2015cites this paper
• Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa

  2015cites this paper
• Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy

  2015cites this paper
• Obstetric Pharmacokinetic Dosing Studies are Urgently Needed

  2014cites this paper
• PBPK Model Describes the Effects of Comedication and Genetic Polymorphism on Systemic Exposure of Drugs That Undergo Multiple Clearance Pathways

  2014cites this paper
• Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.

  2014cites this paper
• Pharmacometrics in pregnancy: An unmet need.

  2014cites this paper
• Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption

  2014cites this paper
• Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4

  2014cites this paper
• Prediction of in vivo metabolite disposition and complex metabolite-dependent drug-drug interactions

  2013cites this paper